促甲状腺激素受体在甲状腺乳头状癌亚型中的表达及临床意义-外科学(腺体)专业论文.docxVIP

目 录 中文摘要·······································································································1 英文摘要·······································································································4 研究论文 促甲状腺激素受体在甲状腺乳头状癌亚型中的表达及临床意义 前言············································································································8 材料与方法······························································································10 结果··········································································································14 附图··········································································································17 附表··········································································································23 讨论··········································································································26 结论··········································································································30 参考文献··································································································32 综述 甲状腺乳头状癌亚型的诊疗进展·······················································35 致谢·······································································································46 个人简历··········································································································47 促甲状腺激素受体在甲状腺乳头状癌亚型中的表达及临床意义 摘 要 目的：近年来甲状腺癌的发病率呈不断增长趋势。其中最常见的是 甲状腺乳头状癌（papillary thyroid carcinoma, PTC），约占甲状腺癌的 80% 。尽管 PTC 预后较好，但复发率却高达 35%。临床观察，侵袭性较 强的 PTC 亚型，复发率较高。所以 PTC 复发可能与 PTC 的治疗方案及病 理亚型相关。目前 PTC 的治疗已达成普遍共识，即手术后加以辅助治疗 的综合治疗。辅助治疗包括 131I 和内分泌治疗。内分泌治疗即促甲状腺激 素（thyroid stimulating hormone，TSH）抑制治疗,是降低分化型甲状腺癌 复发率的重要辅助措施。相关研究表示 TSH 抑制疗效与甲状腺癌细胞促 甲状腺激素受体（thyroid stimulating hormone receptor，TSHR）表达量及 功能相关。一项回顾性研究表示 PTC 患者的复发率与是否行 TSH 抑制治 疗无明显差异。且内分泌治疗存在诸多副作用，影响着 PTC 患者的生存 时间及生活质量。所以研究 PTC 的 TSHR 表达情况，并对 PTC 患者实施 个体治疗迫在眉睫。本实验旨在通过免疫组织化学染色法研究 TSHR 在 PTC 病理亚型中的表达情况，评估 PTC